Celldex Therapeutics, Inc.

DB:TCE2 Stock Report

Market Cap: €2.3b

Celldex Therapeutics Management

Management criteria checks 3/4

Celldex Therapeutics' CEO is Anthony Marucci, appointed in May 2003, has a tenure of 23.08 years. total yearly compensation is $5.37M, comprised of 14.6% salary and 85.4% bonuses, including company stock and options. directly owns 0.053% of the company’s shares, worth €1.24M. The average tenure of the management team and the board of directors is 9 years and 9.1 years respectively.

Key information

Anthony Marucci

Chief executive officer

US$5.4m

Total compensation

CEO salary percentage14.64%
CEO tenure23.1yrs
CEO ownership0.05%
Management average tenure9yrs
Board average tenure9.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Anthony Marucci's remuneration changed compared to Celldex Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$284m

Dec 31 2025US$5mUS$786k

-US$259m

Sep 30 2025n/an/a

-US$225m

Jun 30 2025n/an/a

-US$200m

Mar 31 2025n/an/a

-US$179m

Dec 31 2024US$9mUS$752k

-US$158m

Sep 30 2024n/an/a

-US$154m

Jun 30 2024n/an/a

-US$150m

Mar 31 2024n/an/a

-US$145m

Dec 31 2023US$8mUS$721k

-US$141m

Sep 30 2023n/an/a

-US$125m

Jun 30 2023n/an/a

-US$113m

Mar 31 2023n/an/a

-US$119m

Dec 31 2022US$5mUS$693k

-US$112m

Sep 30 2022n/an/a

-US$106m

Jun 30 2022n/an/a

-US$100m

Mar 31 2022n/an/a

-US$77m

Dec 31 2021US$6mUS$669k

-US$71m

Sep 30 2021n/an/a

-US$72m

Jun 30 2021n/an/a

-US$66m

Mar 31 2021n/an/a

-US$64m

Dec 31 2020US$3mUS$644k

-US$60m

Sep 30 2020n/an/a

-US$48m

Jun 30 2020n/an/a

-US$46m

Mar 31 2020n/an/a

-US$46m

Dec 31 2019US$1mUS$619k

-US$51m

Compensation vs Market: Anthony's total compensation ($USD5.37M) is above average for companies of similar size in the German market ($USD2.22M).

Compensation vs Earnings: Anthony's compensation has been consistent with company performance over the past year.

CEO

Anthony Marucci (64 yo)

23.1yrs
Tenure
US$5,366,709
Compensation

Mr. Anthony S. Marucci, M.B.A., has been the Chief Executive Officer and President of Celldex Therapeutics Inc. since September 2008. He co-founded Celldex Therapeutics Inc. in 2004. Mr. Marucci served as...

Leadership Team

NamePositionTenureCompensationOwnership
Anthony Marucci
Founder23.1yrsUS$5.37m0.053%
€ 1.2m
Tibor Keler
Founder23.1yrsUS$2.12m0.0094%
€ 218.5k
Sam Martin
Senior VP8.9yrsUS$1.83m0.042%
€ 978.7k
Elizabeth Crowley
Chief Product Development Officer & Senior VP11.9yrsUS$1.89m0.012%
€ 269.6k
Margo Heath-Chiozzi
Senior Vice President of Regulatory Affairs8.7yrsUS$1.82m0.018%
€ 424.7k
Joseph Schlessinger
Co-Founder & Member of Scientific Advisory Boardno datano datano data
Sarah Cavanaugh
Senior Vice President of Corporate Affairs & Administration9yrsno datano data
Freddy Jimenez
Senior VP & General Counsel5.4yrsUS$2.17m0.039%
€ 914.8k
Ronald Pepin
Chief Business Officer & Senior VP14.9yrsno data0.026%
€ 597.0k
Diane Young
Senior VP & Chief Medical Officer7yrsUS$2.97mno data
Teri Lawver
SVP & Chief Commercial Officerless than a yearno datano data
9.0yrs
Average Tenure
64yo
Average Age

Experienced Management: TCE2's management team is seasoned and experienced (9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Anthony Marucci
Founder17.5yrsUS$5.37m0.053%
€ 1.2m
Joseph Schlessinger
Co-Founder & Member of Scientific Advisory Board4.8yrsno datano data
Harry Penner
Chairman29.4yrsUS$296.94k0.0036%
€ 82.8k
Herbert Conrad
Independent Director18.3yrsUS$279.45k0.0033%
€ 76.3k
Louis Weiner
Member of Scientific Advisory Boardno datano datano data
James Marino
Independent Director9.3yrsUS$294.43k0.0028%
€ 65.5k
Carl June
Member of Scientific Advisory Boardno datano datano data
Michel Nussenzweig
Member of Scientific Advisory Boardno datano datano data
Marc Rothenberg
Member of Scientific Advisory Boardno datano datano data
Garry Neil
Independent Director4yrsUS$284.45k0%
€ 0
Keith Brownlie
Independent Director9yrsUS$289.44k0.00085%
€ 19.8k
Cheryl Cohen
Independent Director4yrsUS$281.95k0%
€ 0
9.1yrs
Average Tenure
74yo
Average Age

Experienced Board: TCE2's board of directors are considered experienced (9.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/25 04:24
End of Day Share Price 2026/06/25 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Celldex Therapeutics, Inc. is covered by 22 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Etzer DaroutBarclays
Edward NashCanaccord Genuity
Kristen KluskaCantor Fitzgerald & Co.